연구동향 분석

REVIEW : Emerging Therapies for Hepatitis C

( Do Young Kim ) ( Sang Hoon Ahn ) ( Kwang Hyub Han ) 2014년

논문상세정보
인용/피인용
' REVIEW : Emerging Therapies for Hepatitis C' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • 기초의학
  • directactingantiviral
  • hepatitis c
  • pegylatedinterferon
  • ribavirin
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
707 0

0.0%

' REVIEW : Emerging Therapies for Hepatitis C' 의 참고문헌

  • Whitehouse Station
    Victrelis Merck & Co., Inc [2011]
  • Understanding the hepatitis C virus life cycle paves the way for highly effective therapies
    Scheel TK Nat Med 19 : 837 ~ 849 - [2013]
  • Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890
    Hézode C J Hepatol 59 : 434 ~ 441 [2013]
  • The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007
    Ly KN Ann Intern Med 156 : 271 ~ 278 - [2012]
  • Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection
    McHutchison JG N Engl J Med 360 : 1827 ~ 1838 - [2009]
  • Telaprevir for retreatment of HCV infection
    Zeuzem S N Engl J Med 364 : 2417 ~ 2428 - [2011]
  • Telaprevir for previously untreated chronic hepatitis C virus infection
    Jacobson IM N Engl J Med 364 : 2405 ~ 2416 - [2011]
  • Telaprevir for previously treated chronic HCV infection
    McHutchison JG N Engl J Med 362 : 1292 ~ 1303 - [2010]
  • Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study
    Bruno S Hepatology 45 : 579 ~ 587 - [2007]
  • Sustained virologic response in chronic HCV genoptype (GT) 1-infected null responders with combination of daclatasvir (DCV; NS5A inhibitor) and asunaprevir (ASV; NS3 inhibitor) with or without peginterferon alfa-2a/ribavirin (PEG/RBV)
    Lok AS Hepatology 56 (Suppl 1) : 230A ~ - [2012]
  • SovaldiTM (sofosbuvir) tablets, for oral use: US prescribing information
  • Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial
    Kowdley KV Lancet 381 : 2100 ~ 2107 - [2013]
  • Sofosbuvir for previously untreated chronic hepatitis C infection
    Lawitz E N Engl J Med 368 : 1878 ~ 1887 - [2013]
  • Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options
    Jacobson IM N Engl J Med 368 : 1867 ~ 1877 - [2013]
  • Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial
    Zeuzem S Gastroenterology 146 : 430 ~ 441 - [2014]
  • Simeprevir (TMC435) with peginterferon/ribavirin for treatment of chronic HCV genotype-1 infection in treatment-naive patients: results from QUEST-2, a phase III trial
    Manns M J Hepatol 58 (Suppl 1) : S568 ~ [2013]
  • Simeprevir (TMC435) with peginterferon/ribavirin for treatment of chronic HCV genotype 1 infection in patients who relapsed after previous interferon-based therapy: results from PROMISE, a phase III trial
    Lawitz E Gastroenterology 144 (Suppl 1) : S151 ~ - [2013]
  • Simeprevir (TMC435) with peginterferon/ribavirin for chronic HCV genotype 1 infection in treatment-naive patients: results from QUEST-1, a phase III trial
    Jacobson I J Hepatol 58 : S574 ~ - [2013]
  • Safety and efficacy of interferon-free regimens of ABT-450/r, ABT-267, ABT-333 +/- ribavirin in patients with chronic HCV GT1 infection: results from the AVIATOR study
    Kowdley KV J Hepatol 58 (Suppl 1) : S2 ~ - [2013]
  • SVR4 and SVR12 with an interferon-free regimen of BI201335 and BI207127, +/- ribavirin, in treatment-naive patients with chronic genotype-1 HCV infection: interim results of SOUND-C2
    Zeuzem S J Hepatol 56 (Suppl 1) : S45 ~ - [2012]
  • Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders
    Lok AS J Hepatol 60 : 490 ~ 499 - [2014]
  • Randomized study of asunaprevir plus pegylated interferon-α and ribavirin for previously untreated genotype 1 chronic hepatitis C
    Bronowicki JP Antivir Ther 18 : 885 ~ 893 - [2013]
  • Prevalence and genotype distribution of hepatitis C virus among apparently healthy individuals in Mongolia: a population-based nationwide study
    Baatarkhuu O Liver Int 28 : 1389 ~ 1395 - [2008]
  • Predictors of response of US veterans to treatment for the hepatitis C virus
    Backus LI Hepatology 46 : 37 ~ 47 - [2007]
  • Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1
    Kowdley KV N Engl J Med 370 : 222 ~ 232 - [2014]
  • Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection
    McHutchison JG N Engl J Med 361 : 580 ~ 593 - [2009]
  • Outcome of sustained virological responders with histologically advanced chronic hepatitis C
    Morgan TR Hepatology 52 : 833 ~ 844 - [2010]
  • Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naive genotype 1 hepatitis C: the randomized PILLAR study
    Fried MW Hepatology 58 : 1918 ~ 1929 - [2013]
  • New insights into structure and replication of the hepatitis C virus and clinical implications
    Poenisch M Semin Liver Dis 30 : 333 ~ 347 - [2010]
  • Natural history of chronic hepatitis C virus infection
    Ascione A Dig Liver Dis 39 (Suppl 1) : S4 ~ S7 [2007]
  • Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis
    Cardoso AC J Hepatol 52 : 652 ~ 657 - [2010]
  • Faldaprevir plus pegylated interferon alfa-2A and ribavirin in chronic HCV genotype-1 treatment-naive patients: final results from STARTVerso1, a randomized, double blind, placebo-controlled phase III trial
    Ferenci P J Hepatol 58 (Suppl 1) : S569 ~ - [2013]
  • Faldaprevir combined with pegylated interferon alfa-2a and ribavirin in treatment-naive patients with chronic genotype 1 HCV: SILEN-C1 trial
    Sulkowski MS Hepatology 57 : 2143 ~ 2154 - [2013]
  • Faldaprevir and deleobuvir for HCV genotype 1 infection
    Zeuzem S N Engl J Med 369 : 630 ~ 639 - [2013]
  • Factors that predict response of patients with hepatitis C virus infection to boceprevir
    Poordad F Gastroenterology 143 : 608 ~ 618 - [2012]
  • Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial
    Kwo PY Lancet 376 : 705 ~ 716 - [2010]
  • Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection
    Everson GT Gastroenterology 146 : 420 ~ 429 - [2014]
  • Efficacy and safety of boceprevir plus peginterferon-ribavirin in patients with HCV G1 infection and advanced fibrosis/cirrhosis
    Bruno S J Hepatol 58 : 479 ~ 487 - [2013]
  • Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options
    Suzuki Y J Hepatol 58 : 655 ~ 662 - [2013]
  • Daclatasvir: the first of a new class of drugs targeted against hepatitis C virus NS5A
    Gentile I Curr Med Chem 21 : 1391 ~ 1404 - [2014]
  • Daclatasvir: potential role in hepatitis C
    Lee C. Drug Des Devel Ther 7 : 1223 ~ 1233 - [2013]
  • Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection
    Sulkowski MS N Engl J Med 370 : 211 ~ 221 - [2014]
  • Complete SVR4 rates in treatment-naive HCV genotype 1a and 1b patients who achieved vRVR with an interferon-free all-oral regimen
    Sulkowski MS Hepatology 56 (Suppl 1) : 298A ~ - [2012]
  • Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5-year follow-up of 150 patients
    George SL Hepatology 49 : 729 ~ 738 - [2009]
  • Boceprevir for untreated chronic HCV genotype 1 infection
    Poordad F N Engl J Med 364 : 1195 ~ 1206 - [2011]
  • Boceprevir for previously treated chronic HCV genotype 1 infection
    Bacon BR N Engl J Med 364 : 1207 ~ 1217 [2011]
  • Boceprevir for chronic HCV genotype 1 infection in patients with prior treatment failure to peginterferon/ribavirin, including prior null response
    Vierling JM J Hepatol 60 : 748 ~ 756 - [2014]
  • An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases
    Ghany MG Hepatology 54 : 1433 ~ 1444 - [2011]
  • All-oral sofosbuvir-based 12-week regimens for the treatment of chronic HCV infection: the ELECTRON study
    Gane EJ J Hepatol 58 (Suppl 1) : S6 ~ - [2013]
  • A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt
    Sievert W Liver Int 31 (Suppl 2) : 61 ~ 80 - [2011]
  • A randomized trial of daclatasvir with peginterferon alfa-2b and ribavirin for HCV genotype 1 infection
  • A practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis C
    Jacobson IM J Viral Hepat 19 (Suppl 2) : 1 ~ 26 - [2012]
  • A pooled analysis of two randomized, double-blind placebo-controlled phase III trials (STARTVerso 1&2) of faldaprevir plus pegylated interferon alfa-2a and ribavirin in treatment-naive patients with chronic hepatitis C genotype-1 infection
    Jensen DM Hepatology 58 (Suppl 1) : 734A ~ - [2013]
  • A nationwide seroepidemiology of hepatitis C virus infection in South Korea
    Kim do Y Liver Int 33 : 586 ~ 594 [2013]